InvestorsHub Logo
Followers 83
Posts 5662
Boards Moderated 1
Alias Born 10/17/2006

Re: Phaeton post# 23490

Wednesday, 05/17/2017 11:04:38 PM

Wednesday, May 17, 2017 11:04:38 PM

Post# of 32016
Good luck with it.

The other day someone said only Novo and Lilly reps had good access to Endos. For both of them if they bought Afrezza (or any other drug), they'd only be hurting their own sales.

Third place Sanofi is getting killed in the diabetes market.

People think the market cap is really low, but anyone who buys has to pay off their debt. Mannkind had no business ever borrowing money.

They are going to sell shares at 1.10 to pay off interest (and debt) they got into when the stock was at 34.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News